
HOOKIPA Pharma Investor Relations Material
Latest events

AGM 2024
HOOKIPA Pharma

Q1 2025
14 May, 2025

Q4 2024
28 Feb, 2025
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from HOOKIPA Pharma Inc
Access all reports
HOOKIPA Pharma Inc. is a clinical-stage biopharmaceutical company focused on the development of novel immunotherapies for cancer and chronic infectious diseases. The company utilizes a proprietary arenavirus platform, pioneering technologies that engineer arenaviruses to elicit robust and durable antigen-specific T cell responses and pathogen-neutralizing antibodies. HOOKIPA's innovative approach aims to reprogram the immune system to more effectively combat diseases, with its diverse pipeline addressing significant unmet medical needs in various therapeutic areas. The company is headquartered in New York, and its shares are listed on the NASDAQ.
Latest articles
)
David A. Ricks: Eli Lilly's Chairman and CEO
David Ricks built a decades-long career at Eli Lilly, now leading the giant company through a defining moment in its long pharmaceutical history.
3 Jul 2025
)
D. E. Shaw & Co: Inside the Quiet Giant of Quant Finance
A deep dive into D. E. Shaw's evolution from a $28M quant startup to a $65B hedge fund giant, built on research, computing, and quiet consistency.
2 Jul 2025
)
Pershing Square Capital Management: Conviction, Reinvention, and Contrarian Investing
Pershing Square Capital Management has grown into a top-tier hedge fund through reinvention, conviction, and focus on long-term value creation.
2 Jul 2025
Ticker symbol
HOOK
Country
🇺🇸 United States